ASCO 2026

ASCO 2026: Sacituzumab govitecan with pembrolizumab extends PFS for some metastatic triple-negative breast cancer patients

ASCO 2026: Cancer vaccine sustains 49 percent melanoma reduction after 5 years

ASCO 2026: Mobile app for symptom monitoring could help people with advanced cancer maintain their quality of life

ASCO 2026: EMERALD-3 study shows that new combination treatment strategies for embolization-eligible hepatocellular carcinoma are superior

ASCO 2026: Implanted tile-based radiation outperforms stereotactic radiotherapy for treatment of brain metastases

ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue

ASCO 2026: Daraxonrasib doubles median overall survival in metastatic pancreatic cancer

ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage RET fusion-positive NSCLC

ASCO 2026: Potential new targeted treatment option for people with localised high-risk prostate cancer

ASCO 2026: Ivonescimab may improve overall survival in patients with advanced squamous non-small cell lung cancer

ASCO 2026: More accessible oral chemotherapy and ultra-low-dose immunotherapy combo may improve survival and reduce side effects for advanced head and neck cancer

ASCO 2026: Combining targeted immunotherapies with standard R-CHOP delays progression of aggressive B-cell lymphomas

ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma

ASCO 2026: Galleri early detection test may shift timing of cancer detection, reducing stage IV diagnoses

ASCO 2026: Some breast cancer patients with sentinel lymph node spread can safely skip axillary lymph node dissection

ASCO 2026: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

ASCO 2026: Addition of immunotherapy continues to show survival benefit in prolonged follow-up in primary advanced stage or recurrent endometrial cancer

ASCO 2026: Personalised vaccine boosts immune activity against brain cancer

ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST

ASCO 2026: New AI tool may help personalise multiple myeloma treatment

ASCO 2026: Trial tests virus-immunotherapy combination for neuroendocrine tumours

ASCO 2026: Genetic clues may reveal which rare solitary fibrous tumours are more aggressive, likely to spread

ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate cancer

ASCO 2026: Weight loss programme improves physical function, quality of life for patients with breast cancer

ASCO 2026: Fasting before and after chemo may help improve treatment response for some people with ovarian cancer

ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers

Global oncology innovations: B.J. Kennedy award for geriatric oncology

Global disparities in cancer care for conflict-affected populations: Africa's neglected crisis

ASCO 2026: Updates in bladder cancer

ASCO 2026: Updates in renal cancer

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer

Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

STRIDE ± lenvatinib plus TACE improves outcomes in unresectable early-to-intermediate HCC

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

ASCO 2026: Lung cancer roundup

ASCO 2026: Comment: Multi-cancer earlier detection tests

Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced breast cancer

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive mTNBC

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

ASCO 2026: Highlights and analysis

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Bupropion shows benefit for cancer-related fatigue in cancer survivors

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Short-term fasting linked to improved chemo response in advanced ovarian cancer

FMISO PET-guided radiation dose de-escalation maintains long-term outcomes in HPV-associated oropharyngeal cancer

ASCO 2026: Latest in prostate cancer

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

GLP-1 therapy associated with reduced breast cancer risk

Structured exercise programme improves survival and reduces healthcare costs in colon cancer

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Weight loss intervention improves quality of life in breast cancer survivors

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

GLP-1 use linked to improved survival in patients with cancer

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Mobile app-based symptom monitoring helps maintain quality of life in advanced cancer

Aspirin use linked to improved survival in endometrial cancer

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours

Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases

Daraxonrasib nearly doubles survival in previously treated metastatic pancreatic cancer

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Abemaciclib shows benefit in dedifferentiated liposarcoma

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC

ASCO 2026: Latest updates in mRCC

Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

Omission of axillary lymph node dissection reduces arm morbidity without compromising survival in select breast cancer cases

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer

ASCO 2026: Breast cancer overview

Bezuclastinib sunitinib combo shows promise in second-line GIST treatment